DigiBio is focused on improving the effectiveness and efficiency of clinical trials and enabling researchers to collect quality, objective data from trial participants. Our intuitive, user-friendly application platform enables rapid design and deployment of clinical trials. Our patient-facing smartphone app keeps trial participants engaged while collecting meaningful data, helping predict patient outcomes and improved health.
Through its uniquely architected platform, DigiBio accelerates the pace of research and enables clinicians to capitalize on a new wave of research innovation.
DigiBio was first conceived in 2016 from discussions with the Indiana Biosciences Research Institute and biopharma companies who sought a platform to capture digital data directly from patients for clinical trials and research. Bharath Bynagari, based on his healthcare information technology experience at MavenSphere Inc., envisioned a single application platform to efficiently capture data from an unlimited number of clinical trials and can be easily adapted to new clinical protocols or use cases.
This innovative platform is a collaborative creation of MavenSphere and the Indiana Biosciences Research Institute.
Digital biomarkers are emerging in importance in healthcare research and delivery, changing how we approach patient health improvement. Bharath Bynagari founded DigiBio to empower researchers and physicians from all therapeutic areas to take advantage of digital biomarkers in healthcare. While decreasing the cost and improving the efficiency of clinical trials, DigiBio enables validation of digital data as predictive of a person’s health state or response to any therapeutic intervention.